Miransertib

Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research[1]. Miransertib is effective against Leishmania[2].

Product Specifications

CAS Number

[1313881-70-7]

Product Name Alternative

ARQ-092

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Akt; Parasite

Type

Reference compound

Related Pathways

Anti-infection; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/ARQ-092.html

Concentration

10mM

Purity

99.32

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

NC1=NC=CC=C1C2=NC3=CC=C(C4=CC=CC=C4)N=C3N2C5=CC=C(C6(N)CCC6)C=C5

Molecular Formula

C27H24N6

Molecular Weight

432.52

Precautions

H315, H319, H320

References & Citations

[1]Lapierre JM, et al. Discovery of 3- (3- (4- (1-Aminocyclobutyl) phenyl) -5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl) pyridin-2-amine (ARQ 092) : An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. J Med Chem. 2016 Jul 14;59 (13) :6455-69.|[2]Devki Nandan, et al. Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania. PLoS One. 2018 Nov 6;13 (11) :e0206920.